Skye Bioscience Inc (SKYE)

[Paulieme]

Jul. 4, 2017 3:24 AM ET -- Political Risk Increases For Medical Marijuana.--"Several companies such as Nemus Bioscience Inc. (NASDAQ:OTCQB:NMUS) are in fact involved in research to use marijuana derivatives to replace opioids as pain-killers. The recent Eaze Report also showed that those on anti-depressants greatly reduced their dependence on them when they took medical marijuana. They also greatly reduced their alcohol intake. That of course explains why alcohol companies have been major contributors to anti-cannabis campaigns. Nemus Bioscience is a company I have covered before. It is an interesting and professionally managed research company. It is the only such company in the USA which has the approval to grow cannabis for research purposes. This is in conjunction with the University of Mississippi. Of course, that could potentially change under the Trump Administration.
One of its lead CBD candidates is aimed at reducing chronic pain. It is estimated that 100 million Americans suffer from this condition, so the end-market potential is vast.

One of its THC candidates is aimed specifically at eye problems. Latest developments on this were released in a paper given in June. Glaucoma and macular eye degeneration are being targeted in particular. Other conditions Nemus is targeting overlap with those being targeted by GW Pharma.
https://seekingalpha.com/article/4085578-political-risk-increases-medical-marijuana